A meta-analysis and real-world cohort study on the sex-related differences in efficacy and safety of immunotherapy for hepatocellular carcinoma
Balcar L, Scheiner B, Fulgenzi C, D'Alessio A, Pomej K, Roig M, Meyer E, Che J, Nishida N, Lee P, Wu L, Ang C, Krall A, Saeed A, Stefanini B, Cammarota A, Pressiani T, Abugabal Y, Chamseddine S, Wietharn B, Parisi A, Huang Y, Phen S, Vivaldi C, Salani F, Masi G, Bettinger D, Vogel A, von Felden J, Schulze K, Silletta M, Trauner M, Samson A, Wege H, Piscaglia F, Galle P, Stauber R, Kudo M, Singal A, Itani A, Ulahannan S, Parikh N, Cortellini A, Kaseb A, Rimassa L, Chon H, Pinato D, Pinter M
JHEP REP. 2024;6(2):100982.

Characteristics and outcomes of immunotherapy-related liver injury in patients with hepatocellular carcinoma versus other advanced solid tumours
Celsa C, Cabibbo G, Am Fulgenzi C, Scheiner B, Antonio d'Alessio , Manfredi G, Nishida N, Ang C, Marron T, Saeed A, Wietharn B, Pinter M, Cheon J, Huang Y, Lee P, Phen S, Gampa A, Pillai A, Vivaldi C, Salani F, Masi G, Roehlen N, Thimme R, Vogel A, Schönlein M, von Felden J, Schulze K, Wege H, Galle P, Kudo M, Rimassa L, Singal A, El Tomb P, Ulahannan S, Parisi A, Chon H, Hsu W, Stefanini B, Verzoni E, Giusti R, Veccia A, Catino A, Aprile G, Guglielmini P, Di Napoli M, Ermacora P, Antonuzzo L, Rossi E, Verderame F, Zustovich F, Ficorella C, Di Pietro F, Battelli N, Negrini G, Grossi F, Bordonaro R, Pipitone S, Banzi M, Ricciardi S, Laera L, Russo A, De Giorgi U, Cavanna L, Sorarù M, Montesarchio V, Bordi P, Brunetti L, Pinto C, Bersanelli M, Cammà C, Cortellini A, Pinato D
J HEPATOL. 2024;80(3):431-442.

Hepatic decompensation is the major driver of mortality in patients with HCC treated with atezolizumab plus bevacizumab: The impact of successful antiviral treatment
Celsa C, Cabibbo G, Fulgenzi C, Battaglia S, Enea M, Scheiner B, D'Alessio A, Manfredi G, Stefanini B, Nishida N, Galle P, Schulze K, Wege H, Ciccia R, Hsu W, Vivaldi C, Wietharn B, Lin R, Pirozzi A, Pressiani T, Dalbeni A, Natola L, Auriemma A, Rigamonti C, Burlone M, Parisi A, Huang Y, Lee P, Ang C, Marron T, Pinter M, Cheon J, Phen S, Singal A, Gampa A, Pillai A, Roehlen N, Thimme R, Vogel A, Soror N, Ulahannan S, Sharma R, Sacerdoti D, Pirisi M, Rimassa L, Lin C, Saeed A, Masi G, Schönlein M, von Felden J, Kudo M, Cortellini A, Chon H, Cammà C, Pinato D
HEPATOLOGY. 2024 [Epub ahead of print].

Immunotherapy vs Best Supportive Care for Patients With Hepatocellular Cancer With Child-Pugh B Dysfunction
Fulgenzi C, Scheiner B, D'Alessio A, Mehan A, Manfredi G, Celsa C, Nishida N, Ang C, Marron T, Wu L, Saeed A, Wietharn B, Cammarota A, Pressiani T, Pinter M, Sharma R, Cheon J, Huang Y, Lee P, Phen S, Gampa A, Pillai A, Napolitano A, Vivaldi C, Salani F, Masi G, Silletta M, Lo Prinzi F, Di Giacomo E, Vincenzi B, Bettinger D, Thimme R, Vogel A, Schönlein M, von Felden J, Schulze K, Wege H, Galle P, Pirisi M, Park J, Kudo M, Rimassa L, Singal A, El Tomb P, Ulahannan S, Parisi A, Chon H, Hsu W, Ghittoni G, Cammà C, Stefanini B, Trevisani F, Giannini E, Cortellini A, Pinato D
JAMA ONCOL. 2024;10(9):1253-1258.

Radiofrequency ablation via catheter and transpapillary access in patients with cholangiocarcinoma (ACTICCA-2 trial) - a multicenter, randomized, controlled, open-label investigator-initiated trial
Schmidt C, Zapf A, Ozga A, Canbay A, Denzer U, De Toni E, Lohse A, Schulze K, Rösch T, Stein A, Wege H, von Felden J
BMC CANCER. 2024;24(1):.

Efficacy and safety of palliative treatment in patients with autoimmune liver disease-associated hepatocellular carcinoma
Stern L, Schmidt C, Kocheise L, Joerg V, Casar C, Walter A, Drenth J, Papp M, Gatselis N, Zachou K, Pinter M, Scheiner B, Vogel A, Kirstein M, Finkelmeier F, Waidmann O, Weinmann A, Milkiewicz P, Thorburn D, Halliday N, Lleo A, Huber S, Dalekos G, Lohse A, Wege H, von Felden J, Schulze K
ANN HEPATOL. 2024;29(6):101534.

S3-Leitlinie Diagnostik und Therapie biliärer Karzinome: Kurzversion
Bitzer M, Groß S, Albert J, Boda-Heggemann J, Brunner T, Caspari R, De Toni E, Dombrowski F, Evert M, Geier A, Gkika E, Götz M, Helmberger T, Hoffmann R, Huppert P, Kautz A, Krug D, Fougère C, Lang H, Lenz P, Lüdde T, Mahnken A, Nadalin S, Nguyen H, Ockenga J, Oldhafer K, Paprottka P, Pereira P, Persigehl T, Plentz R, Pohl J, Recken H, Reimer P, Riemer J, Ritterbusch U, Roeb E, Rüssel J, Schellhaas B, Schirmacher P, Schlitt H, Schmid I, Schuler A, Seehofer D, Sinn M, Stengel A, Stoll C, Tannapfel A, Taubert A, Tholen R, Trojan J, van Thiel I, Vogel A, Vogl T, Wacker F, Waidmann O, Wedemeyer H, Wege H, Wildner D, Wörns M, Galle P, Malek N
Z GASTROENTEROL. 2023;61(4):420-440.

S3-Leitlinie Diagnostik und Therapie biliärer Karzinome – Langversion
Bitzer M, Groß S, Albert J, Boda-Heggemann J, Brunner T, Caspari R, De Toni E, Dombrowski F, Evert M, Geier A, Gkika E, Götz M, Helmberger T, Hoffmann R, Huppert P, Kautz A, Krug D, Fougère C, Lang H, Lenz P, Lüdde T, Mahnken A, Nadalin S, Nguyen H, Ockenga J, Oldhafer K, Paprottka P, Pereira P, Persigehl T, Plentz R, Pohl J, Recken H, Reimer P, Riemer J, Ritterbusch U, Roeb E, Rüssel J, Schellhaas B, Schirmacher P, Schlitt H, Schmid I, Schuler A, Seehofer D, Sinn M, Stengel A, Stoll C, Tannapfel A, Taubert A, Tholen R, Trojan J, van Thiel I, Vogel A, Vogl T, Wacker F, Waidmann O, Wedemeyer H, Wege H, Wildner D, Wörns M, Galle P, Malek N
Z GASTROENTEROL. 2023;61(4):e92-e156.

Efficacy and safety of atezolizumab/bevacizumab in patients with HCC after prior systemic therapy: A global, observational study
Joerg V, Scheiner B, D Alessio A, Fulgenzi C, Schönlein M, Kocheise L, Lohse A, Huber S, Wege H, Kaseb A, Wang Y, Mathew A, Kuang A, Muzaffar M, Abugabal Y, Chamseddine S, Phen S, Cheon J, Lee P, Balcar L, Krall A, Ang C, Wu L, Saeed A, Huang Y, Bengsch B, Rimassa L, Weinmann A, Stauber R, Korolewicz J, Pinter M, Singal A, Chon H, Pinato D, Schulze K, von Felden J
HEPATOL COMMUN. 2023;7(11):.

EpCAM-positive circulating tumor cells and serum AFP levels predict outcome after curative resection of hepatocellular carcinoma
Kocheise L, Schoenlein M, Behrends B, Joerg V, Casar C, Fründt T, Renné T, Heumann A, Li J, Huber S, Lohse A, Pantel K, Riethdorf S, Wege H, Schulze K, von Felden J
SCI REP-UK. 2023;13(1):20827.

Impact of body mass index in patients receiving atezolizumab plus bevacizumab for hepatocellular carcinoma
Vithayathil M, D'Alessio A, Fulgenzi C, Nishida N, Schönlein M, von Felden J, Schulze K, Wege H, Saeed A, Wietharn B, Hildebrand H, Wu L, Ang C, Marron T, Weinmann A, Galle P, Bettinger D, Bengsch B, Vogel A, Balcar L, Scheiner B, Lee P, Huang Y, Amara S, Muzaffar M, Naqash A, Cammarota A, Zanuso V, Pressiani T, Pinter M, Cortellini A, Kudo M, Rimassa L, Pinato D, Sharma R
HEPATOL INT. 2023;17(4):904-914.

S3-Leitlinie: Diagnostik und Therapie biliärer Karzinome: Langversion 2.0 – Juni 2021 – AWMF-Registernummer: 032-053OL
Bitzer M, Voesch S, Albert J, Bartenstein P, Bechstein W, Blödt S, Brunner T, Dombrowski F, Evert M, Follmann M, La Fougère C, Freudenberger P, Geier A, Gkika E, Götz M, Hammes E, Helmberger T, Hoffmann R, Hofmann W, Huppert P, Kautz A, Knötgen G, Körber J, Krug D, Lammert F, Lang H, Langer T, Lenz P, Mahnken A, Meining A, Micke O, Nadalin S, Nguyen H, Ockenga J, Oldhafer K, Paprottka P, Paradies K, Pereira P, Persigehl T, Plauth M, Plentz R, Pohl J, Riemer J, Reimer P, Ringwald J, Ritterbusch U, Roeb E, Schellhaas B, Schirmacher P, Schmid I, Schuler A, von Schweinitz D, Seehofer D, Sinn M, Stein A, Stengel A, Steubesand N, Stoll C, Tannapfel A, Taubert A, Trojan J, van Thiel I, Tholen R, Vogel A, Vogl T, Vorwerk H, Wacker F, Waidmann O, Wedemeyer H, Wege H, Wildner D, Wittekind C, Wörns M, Galle P, Malek N
Z GASTROENTEROL. 2022;60(2):219-238.

Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child-Pugh A and B cirrhosis: a real-world study
D'Alessio A, Fulgenzi C, Nishida N, Schönlein M, von Felden J, Schulze K, Wege H, Gaillard V, Saeed A, Wietharn B, Hildebrand H, Wu L, Ang C, Marron T, Weinmann A, Galle P, Bettinger D, Bengsch B, Vogel A, Balcar L, Scheiner B, Lee P, Huang Y, Amara S, Muzaffar M, Naqash A, Cammarota A, Personeni N, Pressiani T, Sharma R, Pinter M, Cortellini A, Kudo M, Rimassa L, Pinato D
HEPATOLOGY. 2022;76(4):1000-1012.

Equal Efficacy and Safety Profile in Elderly Patients with Hepatocellular Carcinoma Receiving Palliative Treatment
Fründt T, Casar C, von Felden J, Schöler U, Priebe M, Kraczyk J, Ahrend H, Salamon J, Adam G, Huber S, Lohse A, Wege H, Schulze K
CANCERS. 2022;14(3):.

Circulating tumor cells as a preoperative risk marker for occult metastases in patients with resectable cholangiocarcinoma
Fründt T, von Felden J, Krause J, Heumann A, Li J, Riethdorf S, Pantel K, Huber S, Lohse A, Wege H, Schulze K
FRONT ONCOL. 2022;12:.

Reproducible safety and efficacy of atezolizumab plus bevacizumab for HCC in clinical practice: Results of the AB-real study
Fulgenzi C, Cheon J, D'Alessio A, Nishida N, Ang C, Marron T, Wu L, Saeed A, Wietharn B, Cammarota A, Pressiani T, Personeni N, Pinter M, Scheiner B, Balcar L, Napolitano A, Huang Y, Phen S, Naqash A, Vivaldi C, Salani F, Masi G, Bettinger D, Vogel A, Schönlein M, von Felden J, Schulze K, Wege H, Galle P, Kudo M, Rimassa L, Singal A, Sharma R, Cortellini A, Gaillard V, Chon H, Pinato D
EUR J CANCER. 2022;175:204-213.

Atezolizumab and bevacizumab with transarterial chemoembolization in hepatocellular carcinoma: the DEMAND trial protocol
Khaled N, Seidensticker M, Ricke J, Mayerle J, Oehrle B, Rössler D, Teupser D, Ehmer U, Bitzer M, Waldschmidt D, Fuchs M, Reuken P, Lange C, Wege H, Kandulski A, Dechêne A, Venerito M, Berres M, Luedde T, Kubisch I, Reiter F, De Toni E
FUTURE ONCOL. 2022;18(12):1423-1435.

S3-Leitlinie: Diagnostik und Therapie des hepatozellulären Karzinoms
Sabrina V, Michael B, Jörg A, Peter B, Wolf B, Susanne B, Thomas B, Frank D, Matthias E, Markus F, Christian L, Paul F, Andreas G, Eleni G, Martin G, Elke H, Thomas H, Ralf-Thorsten H, Wolf-Peter H, Peter H, Achim K, Gabi K, Jürgen K, David K, Frank L, Hauke L, Thomas L, Philipp L, Andreas M, Alexander M, Oliver M, Silvio N, Huu Phuc N, Johann O, Karl-Jürgen O, Philipp P, Kerstin P, Philippe P, Thorsten P, Mathias P, Ruben P, Jürgen P, Jutta R, Peter R, Johanna R, Ulrike R, Elke R, Barbara S, Peter S, Irene S, Andreas S, Dietrich v, Daniel S, Marianne S, Alexander S, Andreas S, Nadine S, Christian S, Andrea T, Anne T, Jörg T, Ingo v, Reina T, Arndt V, Thomas V, Hilke V, Frank W, Oliver W, Heiner W, Henning W, Dane W, Christian W, Marcus-Alexander W, Peter G, Nisar M
Z GASTROENTEROL. 2022;60(1):e56-e130.

S3-Leitlinie: Diagnostik und Therapie des hepatozellulären Karzinoms – Kurzversion 2.00 – Juni 2021, AWMF-Registernummer: 032-053OL
Sabrina V, Michael B, Jörg A, Peter B, Wolf B, Susanne B, Thomas B, Frank D, Matthias E, Markus F, Christian L, Paul F, Andreas G, Eleni G, Martin G, Elke H, Thomas H, Ralf-Thorsten H, Wolf-Peter H, Peter H, Achim K, Gabi K, Jürgen K, David K, Frank L, Hauke L, Thomas L, Philipp L, Andreas M, Alexander M, Oliver M, Silvio N, Huu Phuc N, Johann O, Karl-Jürgen O, Philipp P, Kerstin P, Philippe P, Thorsten P, Mathias P, Ruben P, Jürgen P, Jutta R, Peter R, Johanna R, Ulrike R, Elke R, Barbara S, Peter S, Irene S, Andreas S, Dietrich v, Daniel S, Marianne S, Alexander S, Andreas S, Nadine S, Christian S, Andrea T, Anne T, Jörg T, Ingo v, Reina T, Arndt V, Thomas V, Hilke V, Frank W, Oliver W, Heiner W, Henning W, Dane W, Christian W, Marcus-Alexander W, Peter G, Nisar M
Z GASTROENTEROL. 2022;60(1):81-107.

Prognosis of patients with hepatocellular carcinoma treated with immunotherapy - development and validation of the CRAFITY score
Scheiner B, Pomej K, Kirstein M, Hucke F, Finkelmeier F, Waidmann O, Himmelsbach V, Schulze K, von Felden J, Fründt T, Stadler M, Heinzl H, Shmanko K, Spahn S, Radu P, Siebenhüner A, Mertens J, Rahbari N, Kütting F, Waldschmidt D, Ebert M, Teufel A, De Dosso S, Pinato D, Pressiani T, Meischl T, Balcar L, Müller C, Mandorfer M, Reiberger T, Trauner M, Personeni N, Rimassa L, Bitzer M, Trojan J, Weinmann A, Wege H, Dufour J, Peck-Radosavljevic M, Vogel A, Pinter M
J HEPATOL. 2022;76(2):353-363.

Impact of older age in patients receiving atezolizumab and bevacizumab for hepatocellular carcinoma
Vithayathil M, D'Alessio A, Fulgenzi C, Nishida N, Schönlein M, von Felden J, Schulze K, Wege H, Saeed A, Wietharn B, Hildebrand H, Wu L, Ang C, Marron T, Weinmann A, Galle P, Bettinger D, Bengsch B, Vogel A, Balcar L, Scheiner B, Lee P, Huang Y, Amara S, Muzaffar M, Naqash A, Cammarota A, Personeni N, Pressiani T, Pinter M, Cortellini A, Kudo M, Rimassa L, Pinato D, Sharma R
LIVER INT. 2022;42(11):2538-2547.

Der Einsatz der immunonkologischen Therapie beim hepatozellulären Karzinom im Kontext der Lebertransplantation Eine interdisziplinäre Risiko-Nutzen-Abwägung
Vogel A, Sterneck M, Vondran F, Waidmann O, Klein I, Lindig U, Nadalin S, Settmacher U, Tacke F, Schlitt H, Wege H
Z GASTROENTEROL. 2022;60(2):184-191.

Gallengangskrebs: Zu häufig eine zu späte Diagnose
Wege H
MMW Fortschr Med. 2022;164(Suppl 4):19-21.

Real-World Data for Lenvatinib in Hepatocellular Carcinoma (ELEVATOR): A Retrospective Multicenter Study
Welland S, Leyh C, Finkelmeier F, Jefremow A, Shmanko K, Gonzalez-Carmona M, Kandulski A, Jeliazkova P, Best J, Fründt T, Djanani A, Pangerl M, Maieron A, Greil R, Fricke C, Sookthai D, Günther R, Schmiderer A, Wege H, Venerito M, Ehmer U, Müller M, Strassburg C, Weinmann A, Siebler J, Waidmann O, Lange C, Saborowski A, Vogel A
LIVER CANCER. 2022;11(3):219-232.

Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios as Prognostic Biomarkers in Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab
Wu Y, Fulgenzi C, D'Alessio A, Cheon J, Nishida N, Saeed A, Wietharn B, Cammarota A, Pressiani T, Personeni N, Pinter M, Scheiner B, Balcar L, Huang Y, Phen S, Naqash A, Vivaldi C, Salani F, Masi G, Bettinger D, Vogel A, Schönlein M, von Felden J, Schulze K, Wege H, Galle P, Kudo M, Rimassa L, Singal A, Sharma R, Cortellini A, Gaillard V, Chon H, Pinato D, Ang C
CANCERS. 2022;14(23):.

Cabozantinib in Advanced Hepatocellular Carcinoma: Efficacy and Safety Data from an International Multicenter Real-Life Cohort
Finkelmeier F, Scheiner B, Leyh C, Best J, Fründt T, Czauderna C, Beutel A, Bettinger D, Weiß J, Meischl T, Kütting F, Waldschmidt D, Radu P, Schultheiß M, Peiffer K, Ettrich T, Weinmann A, Wege H, Venerito M, Dufour J, Lange C, Pinter M, Waidmann O
LIVER CANCER. 2021;10(4):360-369.

Diagnostic and Prognostic Value of miR-16, miR-146a, miR-192 and miR-221 in Exosomes of Hepatocellular Carcinoma and Liver Cirrhosis Patients
Fründt T, Krause L, Hussey E, Steinbach B, Köhler D, von Felden J, Schulze K, Lohse A, Wege H, Schwarzenbach H
CANCERS. 2021;13(10):2484.

Low incidence of COVID-19 in a prospective cohort of patients with liver cirrhosis and hepatocellular carcinoma treated at a tertiary medical center during the 2020 pandemic
Fründt T, Kuballa L, Lütgehetman M, Nörz D, Arend H, Brehm T, Schulze Zur Wiesch J, Horvatits T, Horvatits K, Huber S, Wege H, Kluwe J
PLOS ONE. 2021;16(12):e0258450.

Assessing the impact of COVID-19 on liver cancer management (CERO-19)
Muñoz-Martínez S, Sapena V, Forner A, Nault J, Sapisochin G, Rimassa L, Sangro B, Bruix J, Sanduzzi-Zamparelli M, Hołówko W, El Kassas M, Mocan T, Bouattour M, Merle P, Hoogwater F, Alqahtani S, Reeves H, Pinato D, Giorgakis E, Meyer T, Villadsen G, Wege H, Salati M, Mínguez B, Di Costanzo G, Roderburg C, Tacke F, Varela M, Galle P, Alvares-da-Silva M, Trojan J, Bridgewater J, Cabibbo G, Toso C, Lachenmayer A, Casadei-Gardini A, Toyoda H, Lüdde T, Villani R, Matilla Peña A, Guedes Leal C, Ronzoni M, Delgado M, Perelló C, Pascual S, Lledó J, Argemi J, Basu B, da Fonseca L, Acevedo J, Siebenhüner A, Braconi C, Meyers B, Granito A, Sala M, Rodríguez Lope C, Blaise L, Romero-Gómez M, Piñero F, Gomez D, Mello V, Pinheiro Alves R, França A, Branco F, Brandi G, Pereira G, Coll S, Guarino M, Benítez C, Anders M, Bandi J, Vergara M, Calvo M, Peck-Radosavljevic M, García-Juárez I, Cardinale V, Lozano M, Gambato M, Okolicsanyi S, Arraez D, Elvevi A, Muñoz A, Lué A, Iavarone M, Reig M
JHEP REP. 2021;3(3):.

NASH limits anti-tumour surveillance in immunotherapy-treated HCC
Pfister D, Núñez N, Pinyol R, Govaere O, Pinter M, Szydlowska M, Gupta R, Qiu M, Deczkowska A, Weiner A, Müller F, Sinha A, Friebel E, Engleitner T, Lenggenhager D, Moncsek A, Heide D, Stirm K, Kosla J, Kotsiliti E, Leone V, Dudek M, Yousuf S, Inverso D, Singh I, Teijeiro A, Castet F, Montironi C, Haber P, Tiniakos D, Bedossa P, Cockell S, Younes R, Vacca M, Marra F, Schattenberg J, Allison M, Bugianesi E, Ratziu V, Pressiani T, D'Alessio A, Personeni N, Rimassa L, Daly A, Scheiner B, Pomej K, Kirstein M, Vogel A, Peck-Radosavljevic M, Hucke F, Finkelmeier F, Waidmann O, Trojan J, Schulze K, Wege H, Koch S, Weinmann A, Bueter M, Rössler F, Siebenhüner A, De Dosso S, Mallm J, Umansky V, Jugold M, Luedde T, Schietinger A, Schirmacher P, Emu B, Augustin H, Billeter A, Müller-Stich B, Kikuchi H, Duda D, Kütting F, Waldschmidt D, Ebert M, Rahbari N, Mei H, Schulz A, Ringelhan M, Malek N, Spahn S, Bitzer M, Ruiz de Galarreta M, Lujambio A, Dufour J, Marron T, Kaseb A, Kudo M, Huang Y, Djouder N, Wolter K, Zender L, Marche P, Decaens T, Pinato D, Rad R, Mertens J, Weber A, Unger K, Meissner F, Roth S, Jilkova Z, Claassen M, Anstee Q, Amit I, Knolle P, Becher B, Llovet J, Heikenwalder M
NATURE. 2021;592(7854):450-456.

Early Detection of Hepatocellular Carcinoma Since the Introduction of the German Clinical Practice Guideline in 2013
Schulze K, Felden J, Fründt T, Krause J, Werner T, Casar C, Jung C, Ittrich H, Sterneck M, Li J, Heumann A, Fischer L, Adam G, Lohse A, Wege H
DTSCH ARZTEBL INT. 2021;118(31-32):540-541.

Sequential Systemic Treatment in Advanced Hepatocellular Carcinoma Is Able to Prolong Median Survival to More than 3 Years in a Selected Real-World Cohort
von Felden J, Karkmann K, Ittrich H, Gil-Ibanez I, Fründt T, Krause J, Lohse A, Wege H, Schulze K
VISC MED. 2021;37(2):87-93.

Rare variants of primary liver cancer: Fibrolamellar, combined, and sarcomatoid hepatocellular carcinomas
Wege H, Schulze K, von Felden J, Calderaro J, Reig M
EUR J MED GENET. 2021;64(11):.

GALAD Score Detects Early Hepatocellular Carcinoma in an International Cohort of Patients With Nonalcoholic Steatohepatitis
Best J, Bechmann L, Sowa J, Sydor S, Dechêne A, Pflanz K, Bedreli S, Schotten C, Geier A, Berg T, Fischer J, Vogel A, Bantel H, Weinmann A, Schattenberg J, Huber Y, Wege H, von Felden J, Schulze K, Bettinger D, Thimme R, Sinner F, Schütte K, Weiss K, Toyoda H, Yasuda S, Kumada T, Berhane S, Wichert M, Heider D, Gerken G, Johnson P, Canbay A
CLIN GASTROENTEROL H. 2020;18(3):728-735.e4.

SOP Transarterielle Chemoembolisation zur Tumortherapie
Ittrich H, Wege H, Schrader J
Gastroenterologie up2date. 2020;2020(16):201-208.

Hepatocellular carcinoma: Intratumoral EpCAM-positive cancer stem cell heterogeneity identifies high-risk tumor subtype
Krause J, von Felden J, Casar C, Fründt T, Galaski J, Schmidt C, Jung C, Ittrich H, Weidemann S, Krech T, Heumann A, Li J, Fischer L, Sauter G, Lohse A, Wege H, Schulze K
BMC CANCER. 2020;20(1):1130.

Perforation of the ascending colon during implantation of an indwelling peritoneal catheter: a case report
Paparoupa M, Wege H, Creutzfeldt A, Sebode M, Uzunoglu F, Boenisch O, Nierhaus A, Izbicki J, Kluge S
BMC GASTROENTEROL. 2020;20(1):345.

Gallengangs- und Gallenblasenkarzinome: auf dem Weg zur personalisierten Therapie
Sinn M, Wege H, Stein A
DEUT MED WOCHENSCHR. 2020;145(7):442-446.

Genetic variation in HSD17B13 reduces the risk of developing cirrhosis and hepatocellular carcinoma in alcohol misusers
Stickel F, Lutz P, Buch S, Nischalke H, Silva I, Rausch V, Fischer J, Weiss K, Gotthardt D, Rosendahl J, Marot A, Elamly M, Krawczyk M, Casper M, Lammert F, Buckley T, McQuillin A, Spengler U, Eyer F, Vogel A, Marhenke S, von Felden J, Wege H, Sharma R, Atkinson S, Franke A, Nehring S, Moser V, Schafmayer C, Spahr L, Lackner C, Stauber R, Canbay A, Link A, Valenti L, Grove J, Aithal G, Marquardt J, Fateen W, Zopf S, Dufour J, Trebicka J, Datz C, Deltenre P, Mueller S, Berg T, Hampe J, Morgan M
HEPATOLOGY. 2020;72(1):88-102.

Elevated Aspartate Aminotransferase to Alanine Aminotransferase Ratio Predicts Poor Outcome in Hepatocellular Carcinoma
von Felden J, Wege H, Schulze K
HEPATOL COMMUN. 2020;4(9):1382-1383.

Doxorubicin-loaded nanoparticles for patients with advanced hepatocellular carcinoma after sorafenib treatment failure (RELIVE): A phase 3 randomised controlled trial
Merle P, Blanc J, Phelip J, Pelletier G, Bronowicki J, Touchefeu Y, Pageaux G, Gerolami R, Habersetzer F, Nguyen-Khac E, Casadei-Gardini A, Borbath I, Tran A, Wege H, Saad A, Colombo M, Abergel A, Richou C, Waked I, Yee N, Molé A, Attali P, Le Boulicaut J, Vasseur B
LANCET GASTROENTEROL. 2019;4(6):454-465.

Vaccinia-based oncolytic immunotherapy Pexastimogene Devacirepvec in patients with advanced hepatocellular carcinoma after sorafenib failure: a randomized multicenter Phase IIb trial (TRAVERSE)
Moehler M, Heo J, Lee H, Tak W, Chao Y, Paik S, Yim H, Byun K, Baron A, Ungerechts G, Jonker D, Ruo L, Cho M, Kaubisch A, Wege H, Merle P, Ebert O, Habersetzer F, Blanc J, Rosmorduc O, Lencioni R, Patt R, Leen A, Foerster F, Homerin M, Stojkowitz N, Lusky M, Limacher J, Hennequi M, Gaspar N, McFadden B, De Silva N, Shen D, Pelusio A, Kirn D, Breitbach C, Burke J
ONCOIMMUNOLOGY. 2019;8(8):1615817.

Programmed cell death protein-1 (PD-1)-targeted immunotherapy in advanced hepatocellular carcinoma: efficacy and safety data from an international multicentre real-world cohort
Scheiner B, Kirstein M, Hucke F, Finkelmeier F, Schulze K, von Felden J, Koch S, Schwabl P, Hinrichs J, Waneck F, Waidmann O, Reiberger T, Müller C, Sieghart W, Trauner M, Weinmann A, Wege H, Trojan J, Peck-Radosavljevic M, Vogel A, Pinter M
ALIMENT PHARM THER. 2019;49(10):1323-1333.

SOP Spontan bakterielle Peritonitis bei Leberzirrhose
Wege H, Kluwe J
Gastroenterologie up2date. 2019;2019(15):321-325.

Treatment Lines in Hepatocellular Carcinoma
Wege H, Li J, Ittrich H
VISC MED. 2019;35(4):266-272.

Versorgung bei kompensierter Leberzirrhose 2018 – Evidenzbasierte prophylaktische Maßnahmen
Karkmann K, Piecha F, Rünzi A, Schulz L, von Wulffen M, Benten D, Kluwe J, Wege H
Z GASTROENTEROL. 2018;56(1):55-69.

Transarterial chemoembolization versus sorafenib in patients with hepatocellular carcinoma and extrahepatic disease
Kirstein M, Voigtländer T, Schweitzer N, Hinrichs J, Marquardt J, Wörns M, Kloeckner R, Fründt T, Ittrich H, Wacker F, Rodt T, Manns M, Wege H, Weinmann A, Vogel A
UNITED EUR GASTROENT. 2018;6(2):238-246.

Fast and facile analysis of glycosylation and phosphorylation of fibrinogen from human plasma-correlation with liver cancer and liver cirrhosis
Nagel T, Klaus F, Ibanez I, Wege H, Lohse A, Meyer B
ANAL BIOANAL CHEM. 2018;410(30):7965-7977.

Correction: Genetic Variants in PNPLA3 and TM6SF2 Predispose to the Development of Hepatocellular Carcinoma in Individuals With Alcohol-Related Cirrhosis
Stickel F, Buch S, Nischalke H, Weiss K, Gotthardt D, Fischer J, Rosendahl J, Marot A, Elamly M, Casper M, Lammert F, McQuillin A, Zopf S, Spengler U, Marhenke S, Kirstein M, Vogel A, Eyer F, von Felden J, Wege H, Buch T, Schafmayer C, Braun F, Deltenre P, Berg T, Morgan M, Hampe J
AM J GASTROENTEROL. 2018;113(7):1099.

Genetic variants in PNPLA3 and TM6SF2 predispose to the development of hepatocellular carcinoma in individuals with alcohol-related cirrhosis
Stickel F, Buch S, Nischalke H, Weiss K, Gotthardt D, Fischer J, Rosendahl J, Marot A, Elamly M, Casper M, Lammert F, McQuillin A, Zopf S, Spengler U, Marhenke S, Kirstein M, Vogel A, Eyer F, von Felden J, Wege H, Buch T, Schafmayer C, Braun F, Deltenre P, Berg T, Morgan M, Hampe J
AM J GASTROENTEROL. 2018;113(10):1475-1483.

Neue Optionen in der Systemtherapie des hepatozellulären Karzinoms
Wege H, Schulze K
TUMORDIAGN THER. 2018;9(39):590-594.

Multi-color RGB marking enables clonality assessment of liver tumors in a murine xenograft model
Thomaschewski M, Riecken K, Unrau L, Volz T, Cornils K, Ittrich H, Heim D, Wege H, Akgün E, Lütgehetmann M, Dieckhoff J, Köpke M, Dandri M, Benten D, Fehse B
ONCOTARGET. 2017;8(70):115582-115595.

High expression of micro RNA-135A in hepatocellular carcinoma is associated with recurrence within 12 months after resection
von Felden J, Heim D, Schulze K, Krech T, Ewald F, Nashan B, Lohse A, Wege H
BMC CANCER. 2017;17(1):60.

Circulating tumor cells as liquid biomarker for high HCC recurrence risk after curative liver resection
von Felden J, Schulze K, Krech T, Ewald F, Nashan B, Pantel K, Lohse A, Riethdorf S, Wege H
ONCOTARGET. 2017;8(52):89978-89987.

Resminostat plus sorafenib as second-line therapy of advanced hepatocellular carcinoma - The SHELTER study
Bitzer M, Horger M, Giannini E, Ganten T, Wörns M, Siveke J, Dollinger M, Gerken G, Scheulen M, Wege H, Zagonel V, Cillo U, Trevisani F, Santoro A, Montesarchio V, Malek N, Holzapfel J, Herz T, Ammendola A, Pegoraro S, Hauns B, Mais A, Lauer U, Henning S, Hentsch B
J HEPATOL. 2016;65(2):280-8.

Systemic inflammation in decompensated cirrhosis Characterization and role in acute-on-chronic liver failure
Clària J, Stauber R, Coenraad M, Moreau R, Jalan R, Pavesi M, Amorós À, Titos E, Alcaraz-Quiles J, Oettl K, Morales-Ruiz M, Angeli P, Domenicali M, Alessandria C, Gerbes A, Wendon J, Nevens F, Trebicka J, Laleman W, Saliba F, Welzel T, Albillos A, Gustot T, Benten D, Durand F, Ginès P, Bernardi M, Arroyo V
HEPATOLOGY. 2016;64(4):1249-64.

Constitutive gp130 activation rapidly accelerates the transformation of human hepatocytes via an impaired oxidative stress response
Heim D, Gil-Ibanez I, Herden J, Parplys A, Borgmann K, Schmidt-Arras D, Lohse A, Rose-John S, Wege H
ONCOTARGET. 2016;7(34):55639-55648.

Inflammation-Induced Expression and Secretion of MicroRNA 122 Leads to Reduced Blood Levels of Kidney-derived Erythropoietin and Anemia
Rivkin M, Simerzin A, Zorde-Khvalevsky E, Chai C, Yuval J, Rosenberg N, Harari-Steinfeld R, Schneider R, Amir G, Condiotti R, Heikenwalder M, Weber A, Schramm C, Wege H, Kluwe J, Galun E, Giladi H
GASTROENTEROLOGY. 2016;151(5):999-1010.e3.

First- and Second-Line Targeted Systemic Therapy in Hepatocellular Carcinoma-An Update on Patient Selection and Response Evaluation
von Felden J, Schulze K, Gil-Ibanez I, Werner T, Wege H
DIAGNOSTICS. 2016;6(4):E44.

Indikationsstellung für operative Eingriffe und perioperatives Management bei Transplantierten und Immunsupprimierten
Wege H, Benten D, Sterneck M
Allgemein- und Viszeralchirurgie up2date. 2016;10(06):453-464.

Different Soluble Forms of the Interleukin-6 Family Signal Transducer gp130 Fine-tune the Blockade of Interleukin-6 Trans-signaling
Wolf J, Waetzig G, Chalaris A, Reinheimer T, Wege H, Rose-John S, Garbers C
J BIOL CHEM. 2016;291(31):16186-96.

Retroviral insertional mutagenesis in telomerase-immortalized hepatocytes identifies RIPK4 as novel tumor suppressor in human hepatocarcinogenesis
Heim D, Cornils K, Schulze K, Fehse B, Lohse A, Brümmendorf T, Wege H
ONCOGENE. 2015;34(3):385-393.

Aktuelle Therapiekonzepte für lokale Cholangiokarzinome
Seehofer D, Brunner T, Wege H
ONKOLOGE. 2015;10:1054 - 1063.

Adjuvant chemotherapy with gemcitabine and cisplatin compared to observation after curative intent resection of cholangiocarcinoma and muscle invasive gallbladder carcinoma (ACTICCA-1 trial) - a randomized, multidisciplinary, multinational phase III trial
Stein A, Arnold D, Bridgewater J, Goldstein D, Jensen L, Klümpen H, Lohse A, Nashan B, Primrose J, Schrum S, Shannon J, Vettorazzi E, Wege H
BMC CANCER. 2015;15:Art. 564.

Transduction of fetal mice with a feline lentiviral vector induces liver tumors which exhibit an E2F activation signature
Condiotti R, Goldenberg D, Giladi H, Schnitzer-Perlman T, Waddington S, Buckley S, Heim D, Cheung W, Themis M, Coutelle C, Simerzin A, Osejindu E, Wege H, Themis M, Galun E
MOL THER. 2014;22(1):59-68.

Specific genomic and transcriptomic aberrations in tumors induced by partial hepatectomy of a chronically inflamed murine liver
Ella E, Heim D, Stoyanov E, Harari-Steinfeld R, Steinfeld I, Pappo O, Perlman T, Nachmansson N, Rivkin L, Olam D, Abramovitch R, Wege H, Galun E, Goldenberg D
ONCOTARGET. 2014;5(21):10318-10331.

TACE plus sorafenib for the treatment of hepatocellular carcinoma: results of the multicenter, phase II SOCRATES trial
Erhardt A, Kolligs F, Dollinger M, Schott E, Wege H, Bitzer M, Gog C, Lammert F, Schuchmann M, Walter C, Blondin D, Ohmann C, Häussinger D
CANCER CHEMOTH PHARM. 2014;74(5):947-954.

Development and validation of a prognostic score to predict mortality in patients with acute-on-chronic liver failure
Jalan R, Saliba F, Pavesi M, Amoros A, Moreau R, Ginès P, Levesque E, Durand F, Angeli P, Caraceni P, Hopf C, Alessandria C, Rodriguez E, Solis-Muñoz P, Laleman W, Trebicka J, Zeuzem S, Gustot T, Mookerjee R, Elkrief L, Soriano G, Cordoba J, Morando F, Gerbes A, Agarwal B, Samuel D, Bernardi M, Arroyo V
J HEPATOL. 2014;61(5):1038-1047.

New foe treated with old guns - supportive role of steroids in the treatment of acute severe hepatitis E
Sebode M, Pischke S, Lütgehetmann M, Polywka S, Quaas A, Lohse A, Wege H
BMC GASTROENTEROL. 2014;14(191):.

The diagnosis and treatment of cholangiocarcinoma
Vogel A, Wege H, Caca K, Nashan B, Neumann U
DTSCH ARZTEBL INT. 2014;111(44):748-54.

Diagnostik und Therapie des hepatozellulären Karzinoms
Greten T, Malek N, Schmidt S, Arends J, Bartenstein P, Bechstein W, Bernatik T, Bitzer M, Chavan A, Dollinger M, Domagk D, Drognitz O, Düx M, Farkas S, Folprecht G, Galle P, Geißler M, Gerken G, Habermehl D, Helmberger T, Herfarth K, Hoffmann R, Holtmann M, Huppert P, Jakobs T, Keller M, Klempnauer J, Kolligs F, Körber J, Lang H, Lehner F, Lordick F, Lubienski A, Manns M, Mahnken A, Möhler M, Mönch C, Neuhaus P, Niederau C, Ocker M, Otto G, Pereira P, Pott G, Riemer J, Ringe K, Ritterbusch U, Rummeny E, Schirmacher P, Schlitt H, Schlottmann K, Schmitz V, Schuler A, Schulze-Bergkamen H, von Schweinitz D, Seehofer D, Sitter H, Straßburg C, Stroszczynski C, Strobel D, Tannapfel A, Trojan J, van Thiel I, Vogel A, Wacker F, Wedemeyer H, Wege H, Weinmann A, Wittekind C, Wörmann B, Zech C
Z GASTROENTEROL. 2013;51(11):1269-326.

The NTPase/helicase domain of hepatitis C virus nonstructural protein 3 inhibits protein kinase C independently of its NTPase activity
Hartjen P, Höchst B, Heim D, von der Kammer H, Lucke J, Reinholz M, Baier A, Smeets R, Wege H, Borowski P, Schulze Zur Wiesch J
CELL MOL BIOL LETT. 2013;18(3):447-58.

Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis
Moreau R, Jalan R, Gines P, Pavesi M, Angeli P, Cordoba J, Durand F, Gustot T, Saliba F, Domenicali M, Gerbes A, Wendon J, Alessandria C, Laleman W, Zeuzem S, Trebicka J, Bernardi M, Arroyo V
GASTROENTEROLOGY. 2013;144(7):1426-37, 1437.e1-9.

Presence of EpCAM-positive circulating tumor cells as biomarker for systemic disease strongly correlates to survival in patients with hepatocellular carcinoma
Schulze K, Gasch C, Staufer K, Nashan B, Lohse A, Pantel K, Riethdorf S, Wege H
INT J CANCER. 2013;133(9):2165-71.

A needle in a haystack: Identifying biomarkers to personalize systemic therapy in patients with hepatocellular carcinoma
Wege H, Brümmendorf T, Gambacorti-Passerini C
HEPATOLOGY. 2013;57(4):1291-3.

Systemtherapie des Leberzellkarzinoms
Wege H, Arnold D
ONKOLOGE. 2012;18(7):602-610.

SU5416 induces premature senescence in endothelial progenitor cells from patients with age-related macular degeneration.
Berna-Thill M, Berna M, Kunst F, Wege H, Strunnikova N, Gordiyenko N, Grierson R, Richard G, Csaky K
MOL VIS. 2011;17:85-98.

Functional p53 is required for effective execution of telomerase inhibition in BCR-ABL-positive CML cells.
Brassat U, Balabanov S, Bali D, Dierlamm J, Balabanov M, Hartmann U, Sirma H, Günes C, Wege H, Fehse B, Gontarewicz A, Dikomey E, Borgmann K, Brümmendorf T
EXP HEMATOL. 2011;39(1):62-66.

Inhibition of experimental HCC growth in mice by use of the kinase inhibitor DMAT.
Sass G, Klinger N, Sirma H, Hashemolhosseini S, Hellerbrand C, Neureiter D, Wege H, Ocker M, Tiegs G
INT J ONCOL. 2011;39(2):433-442.

Rapid quantification of telomerase activity employing an improved real-time telomeric repeat amplification protocol in clinical tissue samples eliminates interference by PCR inhibitors
Schriefer P, Günes C, Wege H
J Cancer Sci Ther. 2011;3(8):176-180.

Forced activation of β-catenin signaling supports the transformation of hTERT-immortalized human fetal hepatocytes.
Wege H, Heim D, Lütgehetmann M, Dierlamm J, Lohse A, Brümmendorf T
MOL CANCER RES. 2011;9(9):1222-1231.

Telomere und Telomerase in Zellalterung und Karzinogenese
Wege H, Brümmendorf T
BIOspektrum. 2010;3:271-273.

Aurora kinase inhibitor PHA-739358 suppresses growth of hepatocellular carcinoma in vitro and in a xenograft mouse model.
Benten D, Keller G, Quaas A, Schrader J, Gontarewicz A, Balabanov S, Balabanov M, Wege H, Moll J, Lohse A, Brümmendorf T
NEOPLASIA. 2009;11(9):934-944.

Hepatic stem and progenitor cells in liver diseases and hepatocarcinogenesis.
Heim D, Wege H
Minerva Gastroenterol Dietol. 2009;55(2):111-121.

Telomeres and telomerase in chronic myeloid leukaemia: impact for pathogenesis, disease progression and targeted therapy.
Keller G, Brassat U, Balabanov M, Heim D, Wege H, Brümmendorf T
HEMATOL ONCOL. 2009;27(3):123-129.

Telomerase-Inhibitoren
Wege H, Brümmendorf T
2009. Molekulare Therapie in der Hämatologie/Onkologie. Bremen: Uni-Med, .

Absence of oncogenic transformation despite acquisition of cytogenetic aberrations in long-term cultured telomerase-immortalized human fetal hepatocytes.
Haker B, Fuchs S, Dierlamm J, Brümmendorf T, Wege H
CANCER LETT. 2007;256(1):120-127.

Telomerase activation in liver regeneration and hepatocarcinogenesis: Dr. Jekyll or Mr. Hyde?
Wege H, Brümmendorf T
CURR STEM CELL RES T. 2007;2(1):31-38.

Regeneration in pig livers by compensatory hyperplasia induces high levels of telomerase activity.
Wege H, Müller A, Müller L, Petri S, Petersen J, Hillert C
Comp Hepatol. 2007;6:6.

Differentiation of human and mouse embryonic stem cells along a hepatocyte lineage
Shirahashi H, Wu J, Yamamoto N, Catana A, Wege H, Wager B, Okita K, Zern M
CELL TRANSPLANT. 2004;13(3):197-211.

In vitro expansion of human hepatocytes is restricted by telomere-dependent replicative aging
Wege H, Chui M, Le H, Strom S, Zern M
CELL TRANSPLANT. 2003;12(8):897-906.

SYBR Green real-time telomeric repeat amplification protocol for the rapid quantification of telomerase activity
Wege H, Chui M, Le H, Tran J, Zern M
NUCLEIC ACIDS RES. 2003;31(2):E3-3.

Telomerase reconstitution immortalizes human fetal hepatocytes without disrupting their differentiation potential
Wege H, Le H, Chui M, Liu L, Wu J, Giri R, Malhi H, Sappal B, Kumaran V, Gupta S, Zern M
GASTROENTEROLOGY. 2003;124(2):432-44.

Cationic lipid polymerization as a novel approach for constructing new DNA delivery agents
Wu J, Lizarzaburu M, Kurth M, Liu L, Wege H, Zern M, Nantz M
BIOCONJUGATE CHEM. 2001;12(2):251-7.

Letzte Aktualisierung aus dem FIS: 21.12.2024 - 04:14 Uhr